Pure Global
NCT06386289

Safety, Performance of CEREGLIDE 92 Intermediate Catheter in Treatment of Acute Ischemic Stroke

Safety, Performance and Lesion Evaluation of Neurothrombectomy Using CEREGLIDE 92 Intermediate Catheter: A Prospective Multi-Center Single-Arm IDE Trial (SPLENDID)
Cerenovus, Part of DePuy Synthes Products, Inc.·ClinicalTrials.gov·device·Device trialNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Acute Ischemic Stroke
Drug/Device/Intervention
Cereglide 92
Study type
Interventional
Intervention type
device
Sponsor & location
Primary sponsor
Cerenovus, Part of DePuy Synthes Products, Inc.
Location
Iowa City,Edison,Valhalla,Nashville,Salt Lake City,Morgantown, United States of America
Timeline & enrollment
Phase
N/A
Start date
Sep 01, 2024
End date
Jun 30, 2026
Enrollment
172 participants
Primary outcome

First pass reperfusion

Summary

The device is indicated for use in the revascularization of patients with acute ischemic
 stroke secondary to intracranial large vessel occlusive disease

ICD-10 classifications
Stroke, not specified as haemorrhage or infarctionSequelae of stroke, not specified as haemorrhage or infarctionCerebral infarctionCerebral infarction, unspecifiedTransient cerebral ischaemic attack, unspecified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06386289
Type
Device Trial
About this record

Access comprehensive clinical trial information for NCT06386289 through Pure Global AI's free database. This phase not specified trial is sponsored by Cerenovus, Part of DePuy Synthes Products, Inc. and is currently Not yet recruiting. The study focuses on Acute Ischemic Stroke. Target enrollment is 172 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.